Challenges in early phase development oncology 17 nov2013
Potential of phase II clinical trials in drug development
ASCOs eighth annual Clinical Cancer Advances report identifies this years most significant clinical cancer advances Highlights 17 most important advances,
Www.OncologyEducation.ca Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized.
Part 2 Colorectal Cancer Thursday, July 26, 2012 7:30 PM – 8:30 PM ET RTP TV: Emerging Treatment Strategies in Colorectal Cancer.
Highlights in the Management of Breast Cancer Rome, May 25-26, 2007 CLINICAL CASE Dott.ssa Jamara Giampietro Cattedra di Oncologia Medica Università G.
2002/10/02 3rd Kitasato-Harvarad Sympo Several Years Experience on Bridging Studies and the Future National Cancer Center Hospital Head, Breast and Medical.
Vervolg CASUS. september 2009 -inmiddels 6 kuren R-CVP ondergaan -restadiering: PR EN NU?
Setting up clinical trials in WM Prof. Dr. C. Buske EWMnetwork London 16.8.2014.
Hyponatremia, Heart Failure, and the role of Tolvaptan (Samsca)
Cetuximab + Capecitabine + Irinotecan (CCI) Versus Cetuximab + Capecitabine + Oxaliplatin (CCO) as 1st-Line Therapy for Patients With Metastatic Colorectal.
Endometrial Committee General Assembly report - David Miller
